Addis, A., Moretti, M.E., Ahmed Syed, F., Einarson, T.R., and Koren, G. (2001). Fetal effects of cocaine: An updated meta-analysis. Reproductive Toxicology, 15(4), 341-369.
Aoki, K., Hirose, Y., and Kuroiwa, Y. (1990). Immunoassay for methamphetamine with a new antibody. Forensic Science International, 44, 245-255.
Appelbaum, P.S., and Grisso, T. (1995). The MacArthur Treatment Competence Study. I: Mental illness and competence to consent to treatment. Law and Human Behavior, 19(2), 105-126.
Berke, J., and Hyman, S. (2000). Addiction, dopamine, and the molecular mechanisms of memory [Review]. Neuron, 25(3), 515-532.
Blaine, J.D., Ling, W., Kosten, T.R., O’Brien, C.P., and Chiarello, R.J. (1994). Establishing the efficacy and safety of medications for the treatment of drug dependence and abuse: Methodological issues. In R. Prien and E. Robinson (Eds.), Clinical evaluation of psychotropic drugs: Principles and guidelines. New York: Raven Press.
Blower, S.M., Schwartz, E.J., and Mills, J. (2003). Forecasting the future of HIV epidemics: The impact of antiretroviral therapies and imperfect vaccines. AIDS Reviews, 5(2), 113-125.
Byrnes-Blake, K.A., Carroll, F.I., Abraham, P., and Owens, S.M. (2001). Generation of anti-(+)methamphetamine antibodies is not impeded by (+)methamphetamine administration during active immunization of rats. International Immunopharmacology, 1(2), 329-338.
Carrera, M.R., Ashley, J.A., Wirsching, P., Koob, G.F., and Janda, K.D. (2001). A second-generation vaccine protects against the psychoactive effects of cocaine. Proceedings of the National Academy of Sciences, USA, 98(4), 1988-1992.
Caulkins, J.P., Rydell, C.P., Schwabe, W., and Chiesa, J. (1997). Mandatory minimum drug sentences: Throwing away the key or the taxpayers’ money? (MR-827-DPRC). Santa Monica, CA: RAND Corporation.
Center for Drug Evaluation and Research. (2003). CDER manual of policies and procedures. Available: http://www.fda.gov/cder/map.htm [November 6, 2003].
Center for Substance Abuse Treatment. (2000). Changing the conversation: Improving substance abuse treatment—The National Treatment Plan Initiative. Rockville, MD: U.S. Department of Health and Human Services.
Cerny, E.H., Levy, R., Mauel, J., Mpandi, M., Mutter, M., Henzelin-Nkubana, C., Patiny, L., Tuchscherer, G., and Cerny, T. (2002). Preclinical development of a vaccine against smoking. Onkologie, 2, 406-411.
Chaloupka, F., and Pacula, R. (2000). Economics and antihealth behavior: The economic analysis of substance use and misuse. In W. Bickel and R. Vuchinich (Eds.), Reframing health behavior change with behavioural economics (pp. 89-111). Mahwah, NJ: Lawrence Erlbaum.
Coffey, R.M., Mark, T., King, E., Harwood, H., McKusick, D., Genuardi, J., Dilonardo, J., and Chalk, M. (2001). National estimates of expenditures for substance abuse treatment, 1997 (DHHS Publication No. SMA-01-3511). Rockville, MD: Center for Substance Abuse Treatment.
Cohen, P.H. (2002). Untreated addiction imposes an ethical bar to recruiting addicts for nontherapeutic studies of addictive drugs. Journal of Law, Medicine and Ethics, 30(1), 73-81.
D’Aunno, T., and Pollack, H.A. (2002). Changes in methadone treatment practices: Results from a national panel study, 1988-2000. Journal of the American Medical Association, 288(7), 850-856.
D’Aunno, T., Vaughn, M., and McElroy, P. (1999). An institutional analysis of HIV prevention efforts by the nation’s outpatient drug abuse treatment units. Journal of Health and Social Behavior, 40, 175-192.
Demain, A.L. (2000). Small bugs, big business. The economic power of the microbe. Biotechnology Advances, 18(6), 499-514.
DeRenzo, E.G. (1994). The ethics of involving psychiatrically impaired persons in research. IRB: A Review of Human Subjects Research, 16(6), 7-9.
Devi, C.M., Bai, M.V., Lal, A.V., Umashankar, P.R., and Krishnan, L.K. (2002). An improved method for isolation of anti-viper venom antibodies from chicken egg yolk. Journal of Biochemical and Biophysical Methods, 51(2), 129-138.
Dresser, R. (1996). Mentally disabled research subjects: The enduring policy issues. Journal of the American Medical Association, 276(1), 67-72.
Ernst, E. (1999). Second thoughts about safety of St. John’s wort [published erratum in Lancet, 355, 580]. Lancet, 354(9195), 2014-2016.
Farrelly, M.C., Bray, J.W., Zarkin, G.A., Wendling, B.W., and Liccardo Pacula, R. (1999). The effects of prices and policies on the demand for marijuana: Evidence from the National Household Surveys on Drug Abuse . (Working Paper No. w6940). Cambridge, MA: National Bureau of Economic Research.
Ferguson, L., Ries, R., and Russo, J. (2003). Barriers to identification and treatment of hazardous drinkers as assessed by urban/rural primary care doctors. Journal of Addictive Diseases, 22(2), 79-90.
Flannery, D.J., Williams, L.L., and Vazsonyi, A.T. (1999). Who are they with and what are they doing? Delinquent behavior, substance use, and early adolescents’ after-school time. American Journal of Orthopsychiatry, 69(2), 247-253.
Fox, B.S., Kantak, K.M., Edwards, M.A., Black, K.M., Bollinger, B.K., Botka, A.J., French, T.L., Thompson, T.L., Schad, V.C., Greenstein, J.L., Gefter, M.L., Exley, M.A., Swain, P.A., and Briner, T.J. (1996). Efficacy of a therapeutic cocaine vaccine in rodent models. Nature Medicine, 2(10), 1129-1132.
Friedmann, P.D., Alexander, J.A., and D’Aunno, T.A. (1999). Organizational correlates of access to primary care and mental health services in drug abuse treatment units. Journal of Substance Abuse Treatment, 16(1), 71-80.
Genevie, L., Struening, E.L., Kallos, J.E., Geiler, I., Muhlin, G.L., and Kalplan, S. (1988). Urban community reaction to health facilities in residential areas: Lessons from the placement of methadone facilities in New York City. International Journal of the Addictions, 23(6), 603-616.
Gold, M.R., Siegel, J.E., Russell, L.B., and Weinstein, M.C. (Eds.). (1996). Cost-effectiveness in health and medicine. New York: Oxford University Press.
Greenstein, R.A., O’Brien, C.P., Woody, G., Long, M., Coyle, G., Grabowski, J., and Vittor, A. (1981). Naltrexone: A short-term treatment alternative for opiate dependence. American Journal of Drug and Alcohol Abuse, 8(3), 291-300.
Griesler, P.C., Kandel, D.B., and Davies, M. (2002). Ethnic differences in predictors of initiation and persistence of adolescent cigarette smoking in the National Longitudinal Survey of Youth. Nicotine and Tobacco Research, 4(1), 79-93.
Harwood, H., Fountain, D., and Livermore, G. (1998). The economic costs of alcohol and drug abuse in the United States, 1992-1998 . (NIH Pub. No. 98-4327). Washington, DC: National Institute on Drug Abuse.
Hieda, Y., Keyler, D.E., Vandevoort, J.T., Kane, J.K., Ross, C.A., Raphael, D.E., Niedbalas, R.S., and Pentel, P.R. (1997). Active immunization alters the plasma nicotine concentration in rats. Journal of Pharmacology and Experimental Therapeutics, 283(3), 1076-1081.
Hieda, Y., Keyler, D.E., Ennifar, S., Fattom, A., and Pentel, P.R. (2000). Vaccination against nicotine during continued nicotine administration in rats: Immunogenicity of the vaccine and effects on cocaine distribution to brain. International Journal of Immunopharmacology, 22(10), 809-819.
Institute of Medicine. (1998). Bridging the gap between practice and research: Forging partnerships with community-based drug and alcohol treatment. Committee on Community-Based Drug Treatment. S. Lamb, M.R. Greenlick, and D. McCarty (Eds.). Washington, DC: National Academy Press.
Johnson, B.D., Rosenblum, A., and Kleber, H. (2003). A new opportunity to expand treatment for heroin users in New York City: Public policy challenges for bringing buprenorphine into drug treatment programs and general medical practice. White Paper for New York City Department of Health and Mental Hygiene. Available: http://www.nyc.gov/html/doh/pdf/public/dmh/whitepaper.pdf [August 21, 2003].
Kabat, G.C. (2003). Fifty years’ experience of reduced-tar cigarettes: What do we know about their health effects? Inhalation Toxicology, 15(11), 1059-1102.
Kantak, K.M., Collins, S.L., Bond, J., and Fox, B.S. (2001). Time course of changes in cocaine self-administration behavior in rats during immunization with the cocaine vaccine IPC-1010. Psychopharmacology, 153(3), 334-340.
Keyler, D.E., Hieda, Y., St. Peter, J., and Pentel, P.R. (1999). Altered disposition of repeated nicotine doses in rats immunized against nicotine. Nicotine Tobacco Research, 1, 241-249.
Kirchmayer, U., Davoli, M., and Verster, A. (2004). Naltrexone maintenance treatment for opioid dependence. In The Cochrane Library (Issue 1). Chichester, England: John Wiley & Sons.
Kleiman, M.A.R. (2004). Costs and benefits of immunotherapies or depot medications for the treatment of drug abuse. In H.J. Harwood and T.G. Myers (Eds.), New treatments for addiction: Behavioral, ethical, legal, and social questions. National Research Council and Institute of Medicine. Washington, DC: The National Academies Press.
Klein, M. (1998). Research issues related to development of medications for treatment of cocaine addiction. Annals of the New York Academy of Sciences, 844, 75-91.
Klesges, L.M., Johnson, K.C., Somes, G., Zbikowski, S., and Robinson, L. (2003). Use of nicotine replacement therapy in adolescent smokers and nonsmokers. Archives of Pediatrics and Adolescent Medicine, 157, 517-522.
Kosten, T.R., Jalali, B., Hogan, I., and Kleber, H.D. (1983). Family denial as a prognostic factor in opiate addict treatment outcome. Journal of Nervous and Mental Disease, 171(10), 611-616.
Kosten, T.R., and Kranzler, H.R. (2004). What will we learn from the FDA clinical trials process and what will we still want to know about immunotherapies and depot medications to treat drug dependence? In H.J. Harwood and T.G. Myers (Eds.), New treatments for addiction: Behavioral, ethical, legal, and social questions. National Research Council and Institute of Medicine. Washington, DC: The National Academies Press.
Kosten, T.R., Rosen, M., Bond, J., Settles, M., Roberts, J.S., Shields, J., Jack, L., and Fox, B. (2002a). Human therapeutic cocaine vaccine: Safety and immunogenecity. Vaccine, 20, 1196-1204.
Kosten, T.R., Gonsa, K., St. Clair Roberts, J., Jack, L., Bond, J., Mitchell, E., and Fox, B. (2002b). Phase II human study of cocaine vaccine TA-CD. Paper prepared for the College on Problems of Drug Dependence Annual Meeting, June 8-13, Quebec City.
Kozlowski, L.T., Goldberg, M.E., Yost, B.A., Ahern, F.M., Aronson, K.R., and Sweeney, C.T. (1996). Smokers are unaware of the filter vents now on most cigarettes: Results of a national survey. Tobacco Control, 5(4), 265-270.
Kozlowski, L.T., Goldberg, M.E., Yost, B.A., White, E.L., Sweeney, C.T., and Pillitteri, J.L. (1998). Smokers’ misperceptions of light and ultra-light cigarettes may keep them smoking. American Journal of Preventive Medicine, 15(1), 9-16.
Kranzler, H.R., Modesto-Lowe, V., and Nuwayser, E.S. (1998) Sustained-release naltrexone for alcoholism treatment: A preliminary study. Alcoholism, Clinical and Experimental Research, 22, 1074-1079.
Krystal, J.H., Cramer, J.A., Krol, W.F., Kirk, G.S., and Rosenheck, R.A. (2001). Veterans Affairs Naltrexone Cooperative Study G. Naltrexone in the treatment of alcohol dependence. New England Journal of Medicine, 345(24), 1734-1739.
Lagrue, G. (1999). Nicotine replacement therapy and smoking cessation: What choice for its status? Bulletin de l’Academie Nationale de Medecine, 183(6), 1175-1182.
Lawrance, K.G. (2001). Adolescent smokers’ preferred smoking cessation methods. Canadian Journal of Public Health, 92(6), 423-426.
Lowinson, J.H., Payte, J.T., Joseph, H., Marion, I.L., and Dole, V.P. (1992). Methadone maintenance. In J.H. Lowinson, P. Ruiz, R.B. Milman, and J.G. Langrod (Eds.), Substance abuse: A comprehensive textbook (pp. 405-414). Philadelphia: Williams and Wilkins.
MacCoun, R., and Reuter, P. (2001). Drug war heresies: Learning from other vices, times, and places. New York: Cambridge University Press.
MacCoun, R.J. (2004). Anticipating unintended consequences of vaccine-like immunotherapies for addictive drug use. In H.J. Harwood and T.G. Myers (Eds.), New treatments for addiction: Behavioral, ethical, legal, and social questions. National Research Council and Institute of Medicine. Washington, DC: The National Academies Press.
Mallat, S.G., and Ismail, N. (2002). Plasmapheresis and related techniques: What should we know. Lebanese Medical Journal, 50(1-2), 45-49.
Mark, T.L., Coffey, R.M., King, E., Harwood, H., McKusick, D., Genuardi, J., Dilondardo, J., and Buck, J.A. (2000). Spending on mental health and substance abuse treatment, 1987-1997. Health Affairs, 19(4), 108-120.
McCrady, B.S., and Bux, D.A. (1999). Ethical issues in informed consent with substance abusers. Journal of Consulting and Clinical Psychology, 67(2), 186-193.
McCuller, W.J., Sussman, S., Dent, C.W., and Teran, L. (2001). Concurrent prediction of drug use among high-risk youth. Addictive Behaviors, 26(1), 137-142.
McLellan, A.T., Lewis, D., O’Brien, C.P., and Kleber, H.D. (2000). Drug addiction as a chronic medical illness: Implications for treatment, insurance and evaluation. Journal of the American Medical Association, 284(13), 1689-1695.
Merton, R.K. (1936). The unanticipated consequences of purposive social action. American Sociological Review, 1, 894-904.
Miller, F.H., and Klanica, K. (2004). Vaccines and immunotherapies to control addiction in minors: The legal framework. In H.J. Harwood and T.G. Myers (Eds.), New treatments for addiction: Behavioral, ethical, legal, and social questions. National Research Council and Institute of Medicine. Washington, DC: The National Academies Press.
National Advisory Council on Alcohol Abuse and Alcoholism. (1988). Recommended council guidelines on ethyl administration in human experimentation. Washington, DC: National Institute on Alcohol Abuse and Alcoholism.
National Advisory Council on Drug Abuse. (1997). Recommended guidelines for the administration of drugs to human subjects. Washington, DC: National Institute on Drug Abuse.
National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. (1978). The Belmont report: Ethical principles and guidelines for the protection of human subjects of research. (Publication No. OS 78-0012). Washington, DC: U.S. Department of Health, Education, and Welfare.
National Research Council. (2001). Informing America’s policy on illegal drugs: What we don’t know keeps hurting us. Committee on Data and Research for Policy on Illegal Drugs. C.F. Mansiki, J.V. Pepper, and C.V. Petrie (Eds.). Committee on Law and Justice and Committee on National Statistics. Commission on Behavioral and Social Sciences and Education. Washington, DC: National Academy Press.
Nohria, N., and Gulati, R. (1995). Is slack good or bad for innovation? Academy of Management Journal, 39, 716-725.
O’Brien, C.P., Childress, A.R., Ehrman, R., and Robbins, S.J. (1998). Conditioning factors in drug use: Can they explain compulsion? Journal of Psychopharmacology, 12(1), 15-22.
O’Connor, P.G., and Samet, J.M. (2002). Substance abuse: The expanding role of general internal medicine. Journal of General Internal Medicine, 17, 398-399.
Office of National Drug Control Policy. (2001). The economic costs of drug abuse in the United States, 1992-1998. (Publication No. NCJ-190636). Washington, DC: Executive Office of the President. Available: http://www.whitehousedrugpolicy.gov/publications/pdf/economic_costs98.pdf [August 21, 2003].
O’Toole, T.P., Strain, E.C., Wand, G., McCaul, M.E., and Barnhart, M. (2002). Outpatient treatment entry and health care utilization after a combined medical/substance abuse intervention for hospitalized medical patients. Journal of General Internal Medicine, 17(5), 334-340.
Owen, P. (2002). The pros and cons of addiction medications. Hazelden Voice, 7, 3-12.
Owens, S.M., Zorbas, M., Lattin, D.L., Gunnell, M., and Polk, M. (1988). Antibodies against arylcyclohexylamines and their similarities in binding specificity with the phencyclidine receptor. Journal of Pharmacology and Experimental Therapeutics, 246, 472-478.
Pentel, P.R. (2004). Vaccines and depot medications for drug addiction: Rationale, mechanisms of action, and treatment implications. In H.J. Harwood and T.G. Myers (Eds.), New treatments for addiction: Behavioral, ethical, legal, and social questions. National Research Council and Institute of Medicine. Washington, DC: The National Academies Press.
Pentel, P.R., and Keyler, D.E. (2004). Vaccination as a treatment for drug abuse: Nicotine, cocaine, phencyclidine. In M.M. Levine (Ed.), New generation vaccines. New York: Marcel Dekker.
Pentel, P.R., Malin, D.H., Ennifar, S., Hieda, Y., Keyler, D.E., Lake, J.R., Milstein, J.R., Basham, L.E., Coy, R.T., Moon, J.W., Naso, R., and Fattom, A. (2000). A nicotine conjugate vaccine reduces nicotine distribution to brain and attenuates its behavioral and cardiovascular effects in rats. Pharmacology, Biochemistry, and Behavior, 65, 191-198.
Pierce, J., Farkas, A., and Evans, N. (1993). Tobacco use in California 1992: A focus on preventing uptake in adolescents. Sacramento: California Department of Human Services.
Plessinger, M.A. (1998). Prenatal exposure to amphetamines: Risks and adverse outcomes in pregnancy. Obstetrics and Gynecology Clinics of North America, 25, 119-138.
Price, J.H., Yingling, F., Dake, J.A., and Telljohann, S.K. (2003). Adolescent smoking cessation services of school-based health centers. Health Education and Behavior, 30(2), 196-208.
Proksch, J.W., Gentry, W.B., and Owens, S.M. (2000). Anti-phencyclidine monoclonal antibodies provide long-term reductions in brain phencyclidine concentrations during chronic phencyclidine administration in rats. Journal of Pharmacology and Experimental Therapeutics, 292(3), 831-837.
Rawson, R.A., McCann, M.J., Hasson, A.J., and Ling, W. (2000). Addiction pharmacotherapy 2000: New options, new challenges. Journal of Psychoactive Drugs, 32, 371-378.
Ridgely, M.S., Iguchi, M.Y., and Chiesa, J. (2004). The use of immunotherapies and sustained-release formulations in the treatment of drug addiction: Will current law support coercion? In H.J. Harwood and T.G. Myers (Eds.), New treatments for addiction: Behavioral, ethical, legal, and social questions. National Research Council and Institute of Medicine. Washington, DC: The National Academies Press.
Robinson, T.E., and Berridge, K.C. (2000). The psychology and neurobiology of addiction: An incentive-sensitization view. Addiction, 95(Suppl 2), S91-S118.
Sagberg, F., Fosser, S., and Saetermo, I.A. (1997). An investigation of behavioural adaptation to airbags and antilock brakes among taxi drivers. Accident, Analysis and Prevention, 29(3), 293-302.
Sargent, J.D., Mott, L.A., and Stevens, M. (1998). Predictors of smoking cessation in adolescents. Archives of Pediatrics and Adolescent Medicine, 152(4), 388-393.
Shimm, D.S., and Speece, R.G. (1992). Rate of refusal to participate in clinical trials. IRB: A Review of Human Subjects Research, 14, 7-9.
Shoeman D., Keyler, D.E., and Pentel, P. (2002). Vaccination of female rats against nicotine reduces nicotine distribution to fetal brain (abstract). Paper presented at the Society for Research on Nicotine and Tobacco Annual Meeting, Savannah, GA.
Sieber, J.E. (1994). Ethical considerations in planning and conducting research on human subjects. Academic Medicine, 68(Suppl 9), 9-13.
Simister, N.E., and Story, C.M. (1997). Human placental Fc receptors and the transmission of antibodies from mother to fetus. Journal of Reproductive Immunology, 37, 1-23.
Simoes, E.A., and Groothuis, J.R. (2002). Respiratory syncytial virus prophylaxis—the story so far. Respiratory Medicine, 96(Suppl B), S15-S24.
Smith, M.D. (1996). Antibody production in plants. Biotechnology Advances, 14(3), 267-281.
Sobeck, J., Abbey, A., Agius, E., Clinton, M., and Harrison, K. (2000). Predicting early adolescent substance use: Do risk factors differ depending on age of onset? Journal of Substance Abuse, 11(1), 89-102.
Stein, M.D., and Friedman, P.D. (2001). Generalist physicians and addiction care: From turfing to sharing the turf. Journal of the American Medical Association, 286, 1764-1765.
Sturm, R., Goldman, W., and McCulloch, J. (1998). Mental health and substance abuse parity: A study of Ohio’s state employee program. Journal of Mental Health Policy and Economics, 1(3), 129-134.
Substance Abuse and Mental Health Services Administration. (2002). National Survey of Substance Abuse Treatment Services (N-SSATS): 2000 data on substance abuse treatment facilities. (Rep. No. DASIS Series: A-16; DHHS Publication No. SMA 02-3668). Rockville, MD: Author.
Substance Abuse and Mental Health Services Administration. (2003). The DAWN report: Trends in drug-related emergency department visits, 1994-2001 at a glance. Available: http://dawninfo.samhsa.gov/pubs_94_02/shortreports/files/TDR_EDvisits_glance_1994_2001.pdf [November 7, 2003].
Swarns, R.L. (1998) Giuliani orders 5 city hospitals to wean addicts off methadone. New York Times, August 15.
Terada, K., Niizuma, T., Ogita, S., and Kataoka, N. (2002). Responses of varicella zoster virus (VZV)-specific immunity in seropositive adults after inhalation of inactivated or live attenuated varicella vaccine. Vaccine, 20(31-32), 3638-3643.
Thomas, C.P. (2000). No magic bullet: Adoption of naltrexone by clinical providers. Dissertation, Brandeis University.
Thomas, C.P., and McCarty, D. (2004). Adoption of drug treatment technology in specialty and primary care settings. In H.J. Harwood and T.G. Myers (Eds.), New treatments for addiction: Behavioral, ethical, legal, and social questions. National Research Council and Institute of Medicine. Washington, DC: The National Academies Press.
Thomas, C.P., Walack, S., Lee, S.S., McCarty, D., and Swift, R. (2003). Research to practice: Factors affecting the adoption of naltrexone in alcoholism treatment. Journal of Substance Abuse Treatment, 24, 1-11.
Thorndike, A.N., Biener, L., and Rigotti, N.A. (2002). Effect on smoking cessation of switching nicotine replacement therapy to over-the-counter status. American Journal of Public Health, 92(3), 437-442.
Tuncok, Y., Hieda, Y., Keyler, D.E., Brown, S., Ennifar, S., Fattom, A., and Pentel, P.R. (2001). Inhibition of nicotine-induced seizures in rats by combining vaccination against nicotine with chronic nicotine infusion. Experimental and Clinical Psychopharmacology, 9(2), 228-234.
U.S. Department of Health and Human Services. (2000). Treating tobacco use and dependence. Washington, DC: U.S. Public Health Service.
Villamor, N. (2003). Mechanism of action and resistance to monoclonal antibody therapy. Seminars in Oncology, 30(4), 424-433.
Vizcarra, C. (2003). New perspectives and emerging therapies for immune-mediated inflammatory disorders. Journal of Infusion Nursing, 26(5), 319-325.
von Sydow, K., Lieb, R., Pfister, H., Hofler, M., and Wittchen, H.U. (2002). What predicts incident use of cannabis and progression to abuse and dependence? A 4-year prospective examination of risk factors in a community sample of adolescents and young adults. Drug and Alcohol Dependence, 68(1), 49-64.
Weissman, M. (2001). Stigma. Journal of the American Medical Association, 285, 261-262.
Wilson, B. (1955). Alcoholics Anonymous: The story of how many thousands of men and women have recovered from alcoholism. New York: Alcoholics Anonymous.
Woody, G.E. (2003). Treating dually diagnosed patients. Psychiatric Times, 20(1), 29-30.
Woody, G.E., and McNichols, L. (2004). Putting addiction treatment medications to use: Lessons learned. In H.J. Harwood and T.G. Myers (Eds.), New treatments for addiction: Behavioral, ethical, legal, and social questions. National Research Council and Institute of Medicine. Washington, DC: The National Academies Press.
World Health Organization. (2003). The history of vaccination. Available: http://www.who.int/vaccines-diseases/history/history.shtml [November 5, 2003].